Rebecca Kelly
Family · Marlton, NJNPI 1710443049
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$951
- Amgen$614
- Regeneron Healthcare Solutions, Inc.$512
- Takeda Pharmaceuticals U.S.A., Inc.$446
- plus $3K from 30 others
What the payments were for
- Consulting fees$801%
- Food & beverage$8,68898%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $1,959 |
| GSK | 73 | $1,128 |
| Sanofi | 34 | $951 |
| Amgen | 29 | $614 |
| Regeneron Healthcare Solutions, Inc. | 14 | $512 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $446 |
| CSL Behring | 21 | $390 |
| Kaleo, Inc. | 20 | $289 |
| Pfizer | 28 | $261 |
| Bio Products Laboratory USA, Inc. | 15 | $212 |
| Novartis | 11 | $210 |
| Grifols USA, LLC | 12 | $209 |
| Genentech USA, Inc. | 11 | $204 |
| LEO Pharma Inc. | 10 | $144 |
| Optinose US, Inc. | 9 | $136 |
| AbbVie | 9 | $121 |
| Biocryst US Sales Co., LLC | 7 | $121 |
| Covis Pharma GmbH | 7 | $113 |
| Aimmune Therapeutics, Inc. | 7 | $102 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $94 |
| Alk-abello, Inc | 5 | $81 |
| ADMA Biomanufacturing LLC | 4 | $80 |
| Incyte Corporation | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 5 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $62 |
| Hikma Pharmaceuticals USA | 3 | $41 |
| Organon | 4 | $39 |
| Merck | 2 | $33 |
| Ionis Pharmaceuticals, Inc. | 2 | $31 |
| GC Biopharma USA, Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $14 |
| USWM, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,838 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 26 | $47,188 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,943 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,317 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,025 |
| Epinephrine | 11 | $2,678 |
| Azelastine Hcl | 41 | $1,366 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $673 |
| Ipratropium Bromide | 14 | $438 |
| Montelukast Sodium | 53 | $338 |
| Fluticasone Propionate | 21 | $286 |
| Famotidine | 20 | $167 |
| Prednisone | 19 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,128 | $29,26030 claims |
| AstraZenecaSymbicort | $1,959 | $4,02513 claims |
| Hikma Pharmaceuticals USAEpinephrine | $41 | $2,67811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Marlton
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
- Toni Michelle SeibertColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.